Selected Publications

Alexandra Weiss MD, Edward L Barnes MD MPH, Meenakshi Bewtra MD PhD MPH : A Practical Guide to the Use of Upadacitinib in Ulcerative Colitis and Crohn's disease American Journal of Gastroenterology November 2023.

James D Lewis, Lauren E Parlett, Michele L Jonsson Funk, Colleen Brensinger, Virginia Pate, Qufei Wu, Ghadeer K Dawwas, Alexandra Weiss, Brad D Constant, Maureen McCauley, Kevin Haynes, Jeff Yufeng Yang, Douglas E Schaubel, Andres Hurtado-Lorenzo, Michael David Kappelman: Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Gastroenterology November 2023.

Weiss AH, Thanawala S, Tang H, Weber A, Buchner A. : Severity of inflammation as a risk factor for the development of colorectal dysplasia in PSC-IBD. (Poster Presentation). DDW May 2023.

Thanawala S, Weiss AH, Weber A, Tang H, Buchner A. : The role of liver transplant in the development of colorectal dysplasia in patients with PSC-IBD. (Poster Presentation). DDW May 2023.

Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Medvedeva E, Xie D, Yang YX: Efficacy of Vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients Inflammatory Bowel Diseases May 2022

Weiss, A.H. and Buchner, A.M: Editorial: colorectal cancer in elderly-onset inflammatory bowel disease—what is the risk? Aliment Pharmacol Ther 56(9): 1421-1422, Nov 2022.

Mahmud N, Weiss A, Trivedi C, Yang YXm Lewis J, Khan N: Risk of venous thromboembolism among patients with inflammatory bowel disease who contract severe acute respiratory syndrome Coronavirus 2. Gastroenterology 161, November 2021.

Weiss AH, Trivedi C, Pernes T, Patel M, Khan N: Incidence of infections and malignancy among elderly IBD patients exposed to vedolizumab, prednisone and mesalamine (Poster Presentation). DDW May 2021.

Weiss AH, Bhattacharya A, Ellison S, Osterman MT, Lichtenstein G: Lower Adalimumab trough levels are associated with higher risk of infectious complications in patients with IBD DDW May 2021.

Ellison S, Weiss AH, Bhattacharya A, Osterman MT, Lichtenstein G: Adalimumab trough concentration is not associated with adverse events in patients with IBD. DDW May 2021.